Avastin and PhIII results, page-2

Nice piece of digging Tewk. Hmmm, it becomes more curious by the minute. Although I'm sitting on the sidelines I'm still very interested in what's going on. Why? Because I want my money back! Ha! Anyway I emailed Tracey today and received a quick response.
These were my questions.
A. When is your next meeting with the FDA?
B. When will you know what went wrong with the control arm?
C. When will you announce the findings of your in depth analysis to the market?
D. One further question which I would love for you to answer but understand if you cannot. If it is found that there is an anomaly with the control related to first line treatment with Avastin causing a spike in control PFS, does Alchemia have the mechanism and finances to run another subgroup trial?

These were her answers.
A. Data analysis complete by end of year and then IF they will meet with the FDA it will be early 2015.
B. Working at completing data analysis by end of year.
C. Didn't know but a material finding would require immediate announcement due continuous disclosure.
D. No answer other than that they are trying to get to the bottom of this 'geographical diffrences'.

One other thing she did say is that the entire portfolio is under review and it will be decided by the end of the year how they will move forward.

So what is it about this geographic difference if not in relation to Avastin. I guess without the data we won't know for sure. Any thoughts?